Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with ... Read More
U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07805486) titled 'Development of a Multimodal Deep Learning Model for Pediatric Patients' on Sept. 01. Brief... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN ... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Invest... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrovi... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the o... Read More